IQVIA beats, raise guidance, signs AI-supported deal with Pfizer across 23 European countries

 

IQVIA beats Q1 2026 estimates, raises FY26 EPS guidance to $12.65–$12.95, signs AI-supported commercial intelligence deal with Pfizer across 23 European countries

• Q1 2026 non-GAAP EPS was $2.90, up 7% YoY and beating estimates.
• Q1 2026 revenue was $4.2B, up 8% YoY, also beating estimates.
• Company reaffirmed full‑year 2026 revenue and EBITDA targets alongside the raised adjusted EPS guidance.

https://finviz.com/quote?t=IQV&p=d